A randomized clinical trial tested whether a digital health program delivered directly to patients could increase lung cancer screening rates among eligible adults. Conducted at two academic health systems,...
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality, but it’s also highly manageable with early recognition, evidence-based treatment, and coordinated care. This guide...
In a large, randomized trial, high-flow nasal oxygen was found noninferior to noninvasive ventilation for most patient groups with acute respiratory failure, though uncertainties remain for...
A randomized trial in moderate chronic obstructive pulmonary disease demonstrated that chest mobility exercises led to greater improvements in lung function and functional capacity compared with...
Patients with chronic obstructive pulmonary disease who recovered from COVID-19 had nearly double the risk of long-term mortality compared with matched controls, with the highest risk observed in severe...
The results from a recent phase 3 trial indicate that mepolizumab significantly reduces moderate and severe exacerbations in patients with eosinophilic chronic obstructive pulmonary disease.
The FDA approved Zongertinib for adults with unresectable or metastatic non-squamous NSCLC with HER2 (ERBB2) TKD activating mutations following prior systemic therapy.
Using national survey data and interpretable machine learning, researchers identified specific per- and polyfluoroalkyl substances that either increase or reduce the risk of chronic obstructive pulmonary...
